Quantcast
Last updated on April 18, 2014 at 6:54 EDT

Latest ZFP technology Stories

2012-01-09 06:00:00

RICHMOND, Calif., Jan. 9, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the initiation of two new Phase 2 clinical studies (SB-728-1101 and SB-728-902, Cohort 5) in its program to develop a "functional cure" for HIV/AIDS. Sangamo's ZFP Therapeutic(®)( )approach (SB-728-T) generates T-cells that are resistant to HIV infection using its zinc finger nuclease (ZFN) technology to permanently disrupt the DNA sequence encoding CCR5, a co-receptor used by HIV to...

2010-07-28 15:00:00

RICHMOND, Calif., July 28 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today reported second quarter 2010 financial results and accomplishments. For the second quarter ended June 30, 2010, Sangamo reported a consolidated net loss of $3.9 million, or $0.09 per share, compared to a net loss of $4.5 million, or $0.11 per share, for the same period in 2009. As of June 30, 2010, the company had cash, cash equivalents, marketable securities and interest receivable of $69.3...

2009-04-29 12:05:00

RICHMOND, Calif., April 29 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today continued success of its zinc finger DNA-binding protein (ZFP) technology. New research published in the scientific journal Nature by licensing partner Dow AgroSciences and Sangamo demonstrated the successful application of ZFP technology for the efficient generation of maize plants with multiple, commercially important traits. The techniques described are broadly applicable across...

2008-12-03 16:07:00

NEW YORK, Dec. 3 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that the company will provide an update on milestones achieved in 2008 and preview objectives for 2009 during its annual Investor and Analyst Briefing to be held in New York City today. David Smoller, Ph.D., President of Sigma-Aldrich Corporation's Research Biotech Business Unit will discuss the progress and expected potential of the two companies' collaboration to commercialize zinc finger...